C/EBPE--STUDY OF A NOVEL MYELOID TRANSCRIPTION FACTOR

C/EBPE--新型骨髓转录因子的研究

基本信息

  • 批准号:
    2882295
  • 负责人:
  • 金额:
    $ 34.83万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1979
  • 资助国家:
    美国
  • 起止时间:
    1979-07-01 至 2003-02-28
  • 项目状态:
    已结题

项目摘要

We have recently cloned a novel human gene (C/EBPepsilon) which is a member of large family of transcriptional factors known as the CCAAT enhancer-binding proteins (C/EBP). C/EBPepsilon is uniquely expressed in granulocytic precursor cells, and this expression is markedly enhanced by retinoids. C/EBP protein exhibits strong and specific binding to double-stranded DNA containing consensus C/EBP sites. Cotransfection of either the sense or anti-sense C/EBPepsilon expression constructs together with CAT-reporter vectors containing myeloid- specific c-mim or human myeloperoxidase promoters suggest a role for C/EBPepsilon in the regulation of a subset of myeloid-specific genes. Likewise, over- and under-expression of C/EBPepsilon in a myeloid line (NB4) increased and decreased the clonal growth of the cells, respectively. Specific Aim 1 will study the modulation of expression of C/EBPepsilon in myeloid cells including: A.) Which myeloid cells express C/EBPepsilon; B.) What is the mechanism by which retinoids induce expression of C/EBPepsilon; C.) How is expression of C/EBPepsilon regulated. In Specific Aim 2, we will determine partners of C/EBPepsilon and how these partners influence the biology of C/EBPepsilon. Using the yeast two hybrid selection system, we have identified CREB2 as one of the frequent partners of C/EBPepsilon. Binding of CREB2 to C/EBPepsilon will be confirmed by several additional in vitro and in vivo techniques and its influence on C/EBPepsilon function will be explored. Other partners of C/EBPepsilon will also be identified and studied. Specific Aim 3 will elucidate biological function of C/EBPepsilon in vitro and in mice. Using both transient and stable sense (S)-and antisense (AS)- expression vectors and oliogonucleotides of C/EBPepsilon, the role that C/EBPepsilon plays in the combinatorial process of myeloid differentiation will be explored using human myeloid cell lines and the murine 32D myeloid cells. In vivo experiments will include: 1.) Study of CMV-driven C/EBPepsilon S- and AS-expressing transgenic mice. 2.) Analysis of C/EBPepsilon germline knock-out mice and C/EBPepsilon deletional chimeras. Specific Aim 4 will dissect the transcriptional activity of the C/EBPepsilon molecule and identify its target genes. The first set of experiments, will define regions of transcriptional activation and repression of the C/EBPepsilon molecule. In further experiments, we will define the consensus binding sequences of C/EBPepsilon using CASTing and whole genome PCR in order to begin to identify novel C/EBPepsilon target sequences and genes. In addition, we will study in detail the ability of C/EBPepsilon to transactivate the myeloperoxidase and neutrophil elastase genes. Taken together, these studies will provide an understanding of C/EBPepsilon, a retinoid inducible, myeloid specific transcriptional activator.
我们最近克隆了一个新的人类基因(C/EB肽), 称为CCAAT的转录因子大家族成员 增强子结合蛋白(C/EBP)。 C/EB肽是唯一表达的 在粒细胞前体细胞中,这种表达明显 被类维生素A强化 C/EBP蛋白具有较强的特异性, 与含有共有C/EBP位点的双链DNA结合。 正义或反义C/EB肽表达的共转染 构建体以及含有髓样- 特异性c-mim或人髓过氧化物酶启动子提示了 C/EB肽在一组骨髓特异性基因调控中的作用 同样,在骨髓细胞系中C/EB肽的过度表达和表达不足, (NB4)增加和减少细胞的克隆生长, 分别 具体目标1将研究表达的调节 C/EB肽在骨髓细胞中的表达,包括:A.)哪些骨髓细胞 表达C/EB肽; B.)类维生素A的作用机制是什么 诱导C/EB肽表达; C.)如何表达C/EB肽 监管.在具体目标2中,我们将确定C/EB Peptide的合作伙伴 以及这些伙伴如何影响C/EB肽的生物学。 使用 酵母双杂交选择系统,我们已经确定CREB 2作为一个 C/EBPeptide的合作伙伴。 CREB 2与C/EB肽的结合 将通过几种额外的体外和体内技术进行证实 并探讨其对C/EB肽功能的影响。 其他 还将鉴定和研究C/EB肽的伙伴。 具体 目的3阐明C/EB肽的体外生物学功能, 对小鼠 使用瞬时和稳定的正义(S)和反义(AS)- C/EB肽的表达载体和寡聚核苷酸, C/EB肽在髓系细胞组合过程中的作用 将使用人髓样细胞系探索分化, 小鼠32 D骨髓细胞。 体内实验将包括:1.)研究 CMV驱动的C/EB肽S-和AS-表达转基因小鼠。 2.)的情况。 C/EBPepsilon种系基因敲除小鼠和C/EBPepsilon的分析 缺失嵌合体具体目标4将剖析转录 C/EB肽分子的活性并鉴定其靶基因。 第一组实验,将定义转录区域, C/EB肽分子的激活和抑制。 进一步 实验中,我们将定义的共识结合序列 C/EBPeptide使用CAST和全基因组PCR,以便开始 鉴定新C/EB肽靶序列和基因。 此外,本发明还提供了一种方法, 我们将详细研究C/EB肽反式激活 髓过氧化物酶和中性粒细胞弹性蛋白酶基因。综上所述各项 研究将提供对C/EB肽的理解, 可诱导骨髓特异性转录激活因子。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Harold Phillip Koeffler其他文献

Harold Phillip Koeffler的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Harold Phillip Koeffler', 18)}}的其他基金

Connecting Genomic Alterations in Liposarcomas with Drug Responses and Identification of New Therapeutic Approaches
将脂肪肉瘤的基因组改变与药物反应联系起来并确定新的治疗方法
  • 批准号:
    9919544
  • 财政年份:
    2016
  • 资助金额:
    $ 34.83万
  • 项目类别:
Connecting Genomic Alterations in Liposarcomas with Drug Responses and Identification of New Therapeutic Approaches
将脂肪肉瘤的基因组改变与药物反应联系起来并确定新的治疗方法
  • 批准号:
    9173247
  • 财政年份:
    2016
  • 资助金额:
    $ 34.83万
  • 项目类别:
CCN Proteins and Breast Cancer
CCN 蛋白与乳腺癌
  • 批准号:
    7847271
  • 财政年份:
    2009
  • 资助金额:
    $ 34.83万
  • 项目类别:
Pax5:Hematopoietic Transcription Factor Involved in ALL
Pax5:参与 ALL 的造血转录因子
  • 批准号:
    8449531
  • 财政年份:
    2009
  • 资助金额:
    $ 34.83万
  • 项目类别:
Pax5:Hematopoietic Transcription Factor Involved in ALL
Pax5:参与 ALL 的造血转录因子
  • 批准号:
    7860682
  • 财政年份:
    2009
  • 资助金额:
    $ 34.83万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    8181107
  • 财政年份:
    2009
  • 资助金额:
    $ 34.83万
  • 项目类别:
Pax5:Hematopoietic Transcription Factor Involved in ALL
Pax5:参与 ALL 的造血转录因子
  • 批准号:
    7735955
  • 财政年份:
    2009
  • 资助金额:
    $ 34.83万
  • 项目类别:
Pax5:Hematopoietic Transcription Factor Involved in ALL
Pax5:参与 ALL 的造血转录因子
  • 批准号:
    8256532
  • 财政年份:
    2009
  • 资助金额:
    $ 34.83万
  • 项目类别:
Charles Drew University/UCLA Cancer Center Partnership to Eliminate Cancer Health
查尔斯德鲁大学/加州大学洛杉矶分校癌症中心合作消除癌症健康
  • 批准号:
    7943032
  • 财政年份:
    2009
  • 资助金额:
    $ 34.83万
  • 项目类别:
Charles Drew University/UCLA Cancer Center Partnership to Eliminate Cancer Health
查尔斯德鲁大学/加州大学洛杉矶分校癌症中心合作消除癌症健康
  • 批准号:
    7789951
  • 财政年份:
    2009
  • 资助金额:
    $ 34.83万
  • 项目类别:

相似海外基金

Development of a method for preserving transplanted lung function using Gapmer-type antisense nucleic acid
开发利用Gapmer型反义核酸保存移植肺功能的方法
  • 批准号:
    22K09003
  • 财政年份:
    2022
  • 资助金额:
    $ 34.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Myostatin antisense nucleic acid therapy for rhabdomyosarcoma
肌肉生长抑制素反义核酸治疗横纹肌肉瘤
  • 批准号:
    21K07762
  • 财政年份:
    2021
  • 资助金额:
    $ 34.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Suppression of PHOX2B (+7Ala mutant) expression by antisense nucleic acid
反义核酸抑制 PHOX2B(7Ala 突变体)表达
  • 批准号:
    20K16927
  • 财政年份:
    2020
  • 资助金额:
    $ 34.83万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Pathogenesis and Antisense nucleic acid, glycosylation supplementation, and AAV therapy development forFukuyama muscular dystrophy and related diseases
福山性肌营养不良症及相关疾病的发病机制和反义核酸、糖基化补充以及 AAV 疗法的开发
  • 批准号:
    20H00526
  • 财政年份:
    2020
  • 资助金额:
    $ 34.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Synthesis of antisense nucleic acid incorporating cyclic sulfonamide backbone
掺入环状磺酰胺主链的反义核酸的合成
  • 批准号:
    20K21245
  • 财政年份:
    2020
  • 资助金额:
    $ 34.83万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Antisense nucleic acid splice correction therapy for Duchenne muscular dystrophy and related disorders
杜氏肌营养不良症及相关疾病的反义核酸剪接校正疗法
  • 批准号:
    G0900887/1
  • 财政年份:
    2011
  • 资助金额:
    $ 34.83万
  • 项目类别:
    Research Grant
CHEMICAL SYNTHESIS OF A NEW MATERIAL OF ANTISENSE NUCLEIC ACID "2'-PHOSPHORYLATED RNAS" -DIRECTED TOWARD ITS BASIC STRUCTURAL STUDIES AND REGULATION OF EXPRESSION OF HIV VIRUS-
反义核酸新材料“2-磷酸化RNAS”的化学合成-针对其基础结构研究和HIV病毒表达调控-
  • 批准号:
    05558090
  • 财政年份:
    1993
  • 资助金额:
    $ 34.83万
  • 项目类别:
    Grant-in-Aid for Developmental Scientific Research (B)
CHEMICAL SYNTHESIS OF A NEW MATERIAL OF ANTISENSE NUCLEIC ACID"2"PHOSTHORYLATEDRNAS" DIRETED TOWARD IIS BASIC STRUCTRAL STUDIES AND REGULATION OF EXPRESSION OF HIV VIRUS-
针对 IIS 基础结构研究和 HIV 病毒表达调控的反义核酸新材料“2”磷酸化 RNA 的化学合成-
  • 批准号:
    04453031
  • 财政年份:
    1992
  • 资助金额:
    $ 34.83万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了